Related Experiment Video
Updated: May 3, 2026
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
Multi-Omics Analysis for Identifying Cell-Type-Specific Druggable Targets in Alzheimer's Disease.
Shiwei Liu1,2, Min Young Cho1,2,3, Yen-Ning Huang1,2
1Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 550 N. University Blvd. Indianapolis, IN, 46202, USA.
This study identifies 27 Alzheimer's disease (AD) candidate causal genes using cell type-specific expression quantitative trait loci (eQTLs) and Genome-Wide Association Study (GWAS) data. Novel astrocyte-specific gene PABPC1 was found, with potential drug targets like imatinib mesylate identified.
Area of Science:
- Genetics
- Neuroscience
- Bioinformatics
Background:
- Expression quantitative trait loci (eQTLs) are crucial for linking genetic variants to disease genes.
- Previous studies integrated Genome-Wide Association Study (GWAS) with tissue-level eQTLs, but lacked cell type-specific analysis for Alzheimer's disease (AD).
- Systematic analysis across AD GWAS datasets and comparison of tissue vs. cell type eQTL effects were missing.
Purpose of the Study:
- To integrate brain cell type-specific eQTL datasets with AD GWAS datasets.
- To identify potential causal genes for AD at the cell type level.
- To explore regulatory mechanisms, pathways, and potential drug repurposing for AD.
Main Methods:
- Utilized Summary Data-Based Mendelian Randomization (SMR) and Bayesian Colocalization (COLOC).
- Integrated five AD GWAS datasets with three single-cell and one bulk tissue eQTL meta-analysis.
- Analyzed enhancer activity, protein-protein interactions, pathway enrichment, and drug signatures.
Main Results:
- Identified 27 candidate causal genes for AD, predominantly in microglia and excitatory neurons.
- Discovered PABPC1 as a novel astrocyte-specific gene linked to AD risk variants near astrocyte-specific enhancers.
- Identified imatinib mesylate as a key drug candidate for AD repurposing.
Conclusions:
- Systematically prioritized AD candidate causal genes using cell type-specific molecular evidence.
- Enhanced understanding of molecular mechanisms underlying AD genetic variants.
- Facilitated interpretation of AD GWAS results and identified potential therapeutic targets.
